Temsirolimus

Temsirolimus
Clinical data
Trade names	Torisel
Other names	CCI-779
AHFS/Drugs.com	Monograph
MedlinePlus	a607071
License data	EU EMA: by INN; US DailyMed: Temsirolimus; US FDA: Torisel;
Pregnancy; category	AU: D; ;
Routes of; administration	Intravenous
ATC code	L01EG01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Metabolism	Liver
Elimination half-life	17.3 hours (temsirolimus); 54.6 hours (sirolimus)
Excretion	Urine (4.6%), faeces (78%)
Identifiers
	IUPAC name (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate;
CAS Number	162635-04-3 ;
PubChem CID	6918289;
IUPHAR/BPS	5892;
DrugBank	DB06287 ;
ChemSpider	21468899 ;
UNII	624KN6GM2T;
KEGG	D06068 ;
ChEMBL	ChEMBL1201182 ;
CompTox Dashboard (EPA)	DTXSID2040945 ;
ECHA InfoCard	100.211.882
Chemical and physical data
Formula	C56H87NO16
Molar mass	1030.303 g·mol−1
	(what is this?) (verify)

Temsirolimus, sold under the brand name Torisel, is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the U.S. Food and Drug Administration (FDA) in May 2007,^[3] and was also approved by the European Medicines Agency (EMA) in November 2007.^[1] It is a derivative and prodrug of sirolimus.

^ ^a ^b "Torisel EPAR". European Medicines Agency. 17 September 2018. Retrieved 6 November 2020.
^ ^a ^b Temsirolimus Drug Monograph. Cancer Care Ontario. June 2014. p. 2.
^ "FDA Approves New Drug for Advanced Kidney Cancer" (Press release). U.S. Food and Drug Administration (FDA). May 30, 2007. Archived from the original on October 16, 2012. Retrieved October 15, 2013.